BY Maria Outze

Novo Nordisk’s diabetic issues tablet computer prospect makes Tough Biotech’s checklist of 2025’s greatest professional test frustrations.

After a turbulent duration, Hans Schambye is tipping down as chief executive officer of Galecto. He will certainly rather end up being the brand-new chief executive officer of biot…

Donald Trump’s supposed Many Preferred Country plan is requiring business to make tough selections in between markets, according to the chief executive officer of Novo Nordis…

The FDA has actually signified a significant suppression on business mass-marketing unlawful imitator medicines, consisted of worsened variations of preferred GLP-1 medicines. This…

The Danish biotech firm goes for DKK 37.3 bn in earnings by 2030. “Ascendis is going into a stage of quick development,” chief executive officer claims.

Recently, 38,423 brand-new prescriptions for Wegovy tablet computers were given to insured people in the USA.

Merck’s Belén Garijo will certainly end up being chief executive officer of the French pharmaceutical business.

According to sector media electrical outlet Biopharma Dive, the collaboration might be worth as much as USD 1.7 bn.

The Danish biotech business will certainly offer over 14 million brand-new shares and offer financial institutions the chance to acquire extra shares.